Related Experiment Video
Updated: Aug 15, 2025
Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
Published on: June 30, 2019
The Inhibitory Properties of a Novel, Selective LMTK3 Kinase Inhibitor
Alessandro Agnarelli1, Andrea Lauer Betrán1, Athanasios Papakyriakou2
1Department of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.
Abstract:
Recently, the oncogenic role of lemur tyrosine kinase 3 (LMTK3) has been well established in different tumor types, highlighting it as a viable therapeutic target. In the present study, using in vitro and cell-based assays coupled with biophysical analyses, we identify a highly selective small molecule LMTK3 inhibitor, namely C36. Biochemical/biophysical and cellular studies revealed that C36 displays a high in vitro selectivity profile and provides notable therapeutic effect when tested in the National Cancer Institute (NCI)-60 cancer cell line panel. We also report the binding affinity between LMTK3 and C36 as demonstrated via microscale thermophoresis (MST). In addition, C36 exhibits a mixed-type inhibition against LMTK3, consistent with the inhibitor overlapping with both the adenosine 5'-triphosphate (ATP)- and substrate-binding sites. Treatment of different breast cancer cell lines with C36 led to decreased proliferation and increased apoptosis, further reinforcing the prospective value of LMTK3 inhibitors for cancer therapy.
Insights
Researchers identified C36, a selective small molecule inhibitor targeting lemur tyrosine kinase 3 (LMTK3). This compound shows therapeutic effects in cancer cells, demonstrating potential for LMTK3-targeted cancer therapies.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Lemur tyrosine kinase 3 (LMTK3) plays a significant role in oncogenesis.
- LMTK3 is recognized as a potential therapeutic target for various cancers.
Purpose of the Study:
- To identify and characterize a novel, highly selective small molecule inhibitor of LMTK3.
- To evaluate the therapeutic potential of the identified inhibitor in cancer models.
Main Methods:
- In vitro and cell-based assays were employed.
- Biophysical analyses, including microscale thermophoresis (MST), were utilized.
- The inhibitor's effect was tested on the National Cancer Institute (NCI)-60 cancer cell line panel and breast cancer cell lines.
Main Results:
- A highly selective LMTK3 inhibitor, C36, was identified.
- C36 demonstrated significant in vitro selectivity and therapeutic effects across the NCI-60 panel.
- Microscale thermophoresis confirmed the binding affinity between LMTK3 and C36.
- C36 exhibited mixed-type inhibition, binding to both ATP and substrate sites.
- Treatment with C36 reduced proliferation and increased apoptosis in breast cancer cell lines.
Conclusions:
- C36 is a potent and selective LMTK3 inhibitor with demonstrated therapeutic efficacy.
- The findings support the development of LMTK3 inhibitors as a promising strategy for cancer therapy.
